Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more
Sonoma Pharmaceuticals Inc (SNOA) - Total Assets
Latest total assets as of December 2025: $13.62 Million USD
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) holds total assets worth $13.62 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sonoma Pharmaceuticals Inc - Total Assets Trend (2002–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sonoma Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Sonoma Pharmaceuticals Inc's total assets of $13.62 Million consist of 92.4% current assets and 7.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.3% |
| Accounts Receivable | $3.76 Million | 27.5% |
| Inventory | $2.92 Million | 21.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sonoma Pharmaceuticals Inc's current assets represent 92.4% of total assets in 2025, an increase from 45.3% in 2002.
- Cash Position: Cash and equivalents constituted 39.3% of total assets in 2025, down from 45.3% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 27.5% of total assets.
Sonoma Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Sonoma Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Sonoma Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sonoma Pharmaceuticals Inc generates 1.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sonoma Pharmaceuticals Inc is currently not profitable relative to its asset base.
Sonoma Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 3.34 | 3.18 |
| Quick Ratio | 2.00 | 2.49 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.93 Million | $ 8.68 Million | $ 8.90 Million |
Sonoma Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Sonoma Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | $13.69 Million |
| Market Capitalization | $4.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sonoma Pharmaceuticals Inc's assets below their book value (0.30 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sonoma Pharmaceuticals Inc's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sonoma Pharmaceuticals Inc (2002–2025)
The table below shows the annual total assets of Sonoma Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $13.69 Million | -7.10% |
| 2024-03-31 | $14.74 Million | -9.19% |
| 2023-03-31 | $16.23 Million | -13.87% |
| 2022-03-31 | $18.84 Million | +25.74% |
| 2021-03-31 | $14.99 Million | +2.93% |
| 2020-03-31 | $14.56 Million | +0.78% |
| 2019-03-31 | $14.45 Million | -24.77% |
| 2018-03-31 | $19.21 Million | -24.56% |
| 2017-03-31 | $25.46 Million | +84.45% |
| 2016-03-31 | $13.80 Million | -8.27% |
| 2015-03-31 | $15.05 Million | -27.62% |
| 2014-03-31 | $20.79 Million | +65.47% |
| 2013-03-31 | $12.56 Million | +60.31% |
| 2012-03-31 | $7.84 Million | -9.53% |
| 2011-03-31 | $8.66 Million | -15.21% |
| 2010-03-31 | $10.22 Million | +87.59% |
| 2009-03-31 | $5.45 Million | -76.93% |
| 2008-03-31 | $23.61 Million | -12.39% |
| 2007-03-31 | $26.95 Million | +112.39% |
| 2006-03-31 | $12.69 Million | +82.84% |
| 2005-03-31 | $6.94 Million | +622.16% |
| 2003-03-31 | $961.00K | -43.03% |
| 2002-03-31 | $1.69 Million | -- |